Trial · NCT07894107
Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
NCT07894107, Recruiting, Beijing Tiantan Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome. Trials, record NCT07894107. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07894107
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- NCT number
- NCT07894107
- Status
- Recruiting
- Enrollment
- 3,000 participants, estimated
- Lead sponsor
- Beijing Tiantan Hospital
- Conditions
- Moyamoya Disease, Moyamoya Syndrome
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of stroke within 24 months after enrollment | From enrollment through 24 months | Stroke is defined as symptomatic ischemic stroke or intracerebral hemorrhage occurring after enrollment. Suspected stroke events will be identified through scheduled or event-driven follow-up, telephone interviews, and review of hospitalization records and will be confirmed by brain CT or MRI whenever available. The outcome will be reported as the percentage of participants experiencing at least one incident stroke within 24 months after enrollment. |
| Secondary | Incidence of stroke within 6 months after enrollment | From enrollment through 6 months | Stroke is defined as symptomatic ischemic stroke or intracerebral hemorrhage occurring after enrollment and confirmed by clinical records and brain CT or MRI whenever available. The outcome will be reported as the percentage of participants experiencing at least one incident stroke within 6 months after enrollment. |
| Secondary | Incidence of stroke within 12 months after enrollment | From enrollment through 12 months | Stroke is defined as symptomatic ischemic stroke or intracerebral hemorrhage occurring after enrollment and confirmed by clinical records and brain CT or MRI whenever available. The outcome will be reported as the percentage of participants experiencing at least one incident stroke within 12 months after enrollment. |
| Secondary | Incidence of transient ischemic attack within 24 months | From enrollment through 24 months | Transient ischemic attack is defined as an acute focal neurological deficit attributable to cerebral ischemia that completely resolves within 24 hours without evidence of a new cerebral infarction on CT or MRI. The outcome will be reported as the percentage of participants experiencing at least one transient ischemic attack during follow-up. |
| Secondary | Number of transient ischemic attack episodes within 24 months | From enrollment through 24 months | The total number of protocol-defined transient ischemic attack episodes occurring in each participant during follow-up will be recorded. The outcome will be reported as the number of transient ischemic attack episodes per participant. |
| Secondary | Incidence of disabling stroke within 24 months | From enrollment through 24 months | Disabling stroke is defined as an incident stroke associated with a modified Rankin Scale score greater than 1, according to the study protocol. The outcome will be reported as the percentage of participants experiencing a disabling stroke. |
| Secondary | Participants with an increase of at least 1 point in the modified Rankin Scale score at 6 months | Baseline to 6 months | Neurological disability will be assessed using the modified Rankin Scale, which ranges from 0 to 6, with higher scores indicating greater disability. The outcome will be reported as the percentage of participants whose modified Rankin Scale score increases by at least 1 point from baseline. |
| Secondary | Participants with an increase of at least 1 point in the modified Rankin Scale score at 12 months | Baseline to 12 months | Neurological disability will be assessed using the modified Rankin Scale, which ranges from 0 to 6, with higher scores indicating greater disability. The outcome will be reported as the percentage of participants whose modified Rankin Scale score increases by at least 1 point from baseline. |
| Secondary | Participants with an increase of at least 1 point in the modified Rankin Scale score at 24 months | Baseline to 24 months | Neurological disability will be assessed using the modified Rankin Scale, which ranges from 0 to 6, with higher scores indicating greater disability. The outcome will be reported as the percentage of participants whose modified Rankin Scale score increases by at least 1 point from baseline. |
| Secondary | All-cause mortality within 24 months | From enrollment through 24 months | The outcome will be reported as the percentage of participants who die from any cause during follow-up. |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07894107
GET https://conductscience.org/api/trials/v1/NCT07894107/registered